PL378369A1 - Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji - Google Patents

Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji

Info

Publication number
PL378369A1
PL378369A1 PL378369A PL37836904A PL378369A1 PL 378369 A1 PL378369 A1 PL 378369A1 PL 378369 A PL378369 A PL 378369A PL 37836904 A PL37836904 A PL 37836904A PL 378369 A1 PL378369 A1 PL 378369A1
Authority
PL
Poland
Prior art keywords
vomiting
retching
combination
treating nausea
nausea
Prior art date
Application number
PL378369A
Other languages
English (en)
Polish (pl)
Inventor
Steven B. Landau
Cheryl L. Miller
Karl Bruce Thor
Original Assignee
Dynogen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals, Inc. filed Critical Dynogen Pharmaceuticals, Inc.
Publication of PL378369A1 publication Critical patent/PL378369A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Dental Preparations (AREA)
PL378369A 2003-01-13 2004-01-13 Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji PL378369A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44007603P 2003-01-13 2003-01-13
US49247803P 2003-08-04 2003-08-04

Publications (1)

Publication Number Publication Date
PL378369A1 true PL378369A1 (pl) 2006-04-03

Family

ID=32718144

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378369A PL378369A1 (pl) 2003-01-13 2004-01-13 Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji

Country Status (14)

Country Link
US (3) US20040147510A1 (enExample)
EP (1) EP1567163B1 (enExample)
JP (1) JP2006516977A (enExample)
KR (1) KR20050094843A (enExample)
AT (1) ATE359079T1 (enExample)
AU (1) AU2004204827B2 (enExample)
BR (1) BRPI0406748A (enExample)
CA (1) CA2512022A1 (enExample)
DE (1) DE602004005814T2 (enExample)
ES (1) ES2285407T3 (enExample)
MX (1) MXPA05007379A (enExample)
NZ (1) NZ541009A (enExample)
PL (1) PL378369A1 (enExample)
WO (1) WO2004062624A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
EP1539172A1 (en) * 2002-08-29 2005-06-15 Arachnova Therapeutics Ltd. New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidine
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
BRPI0406749A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
WO2005007600A2 (en) * 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
WO2006066197A1 (en) * 2004-12-17 2006-06-22 Janssen Pharmaceutica, N.V. Tetrahydroisoquinoline compounds for treatment of cns disorders
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1906951A4 (en) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL HYPOMOTILITY AND RELEVANT DISEASES
WO2007090113A2 (en) * 2006-02-01 2007-08-09 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
US20070254899A1 (en) * 2006-03-31 2007-11-01 Dynogen Pharmaceuticals, Inc. Soluble salts of thieno[2,3-d]pyrimidine derivatives
US20070259933A1 (en) * 2006-05-04 2007-11-08 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
WO2008038106A1 (en) * 2006-09-27 2008-04-03 Orchid Chemicals & Pharmaceuticals Limited Venlafaxine extended release formulations
KR101779991B1 (ko) * 2009-05-20 2017-09-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 병소성 전정 질환을 치료하기 위한 세로토닌 5-ｈｔ3 수용체 길항제의 용도
RU2679448C2 (ru) 2013-03-14 2019-02-11 Редхилл Байофарма Лтд. Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением
MX373002B (es) 2014-03-11 2020-04-30 Redhill Biopharma Ltd Formas de dosificacion sólida de liberación extendida de ondansetrón para tratar bien sea síntomas de náusea, vómito o diarrea
PL3442537T3 (pl) 2016-04-14 2024-07-15 Sensorion (+)-azasetron do zastosowania w leczeniu zaburzeń ucha
WO2022015628A2 (en) * 2020-07-15 2022-01-20 St. Jude Children's Research Hospital, Inc. Obese ferret model and methods of establishing and using the same
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023164132A1 (en) * 2022-02-25 2023-08-31 Neuraxis, Inc. Auricular nerve field stimulation device and methods for using the same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36500A (en) * 1862-09-23 Joseph banks
US44450A (en) * 1864-09-27 Improvement in ore-crushers
US254172A (en) * 1882-02-28 Half to laweence
US107244A (en) * 1870-09-13 Improved manner of treating- cod-liver and castor-oils
US254171A (en) * 1882-02-28 Car-axle box
US48874A (en) * 1865-07-18 Improved extension door-knobs
US203055A (en) * 1878-04-30 Improvement in carpet-stretchers
US36549A (en) * 1862-09-23 Improvement in caps
US4225407A (en) * 1979-04-04 1980-09-30 The Dow Chemical Company Cathodic electrodeposition of polymers onto a conductive surface
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
DE3689974T2 (de) * 1985-03-14 1994-11-03 Beecham Group Plc Arzneimittel zur Behandlung von Emesis.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
EP0297651B1 (en) * 1987-06-29 1993-11-03 Duphar International Research B.V Anellated indole derivatives
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
US5530008A (en) * 1989-04-21 1996-06-25 Sandoz Ltd. Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
GB9214184D0 (en) 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
HUP9901208A3 (en) * 1995-07-28 2002-10-28 Dainippon Pharmaceutical Co (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methyl-amino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
KR100469029B1 (ko) * 1996-02-15 2005-05-27 얀센 파마슈티카 엔.브이. 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도
DE69816060T2 (de) * 1997-04-18 2004-04-22 Janssen Pharmaceutica N.V. Verwendung von 5ht3 antagonisten zum fördern der darmspülung
JPH10298078A (ja) 1997-05-06 1998-11-10 Mitsubishi Chem Corp 抗不安薬
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
US6117879A (en) * 1997-09-16 2000-09-12 Solvay Pharmaceuticals Gmbh Methods of using moxonidine to inhibit nociceptive pain
EP0901790B1 (en) * 1997-09-16 2001-05-30 Solvay Pharmaceuticals GmbH Use of moxonidine for the Treatment of neuropathic pain
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
US6376550B1 (en) * 1999-02-09 2002-04-23 Asta Medica Ag Pharmaceutical compositions containing tramadol for migraine
AU3422800A (en) * 1999-02-18 2000-09-04 Novartis Ag Use of 5-ht3 receptor antagonists
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6589570B1 (en) * 1999-04-12 2003-07-08 University Of Madras Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
ES2247572T3 (es) * 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar las cefaleas migrañosas.
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0112494D0 (en) 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
CA2473392A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
AU2003255712B2 (en) 2002-07-10 2007-03-15 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-D) pyrimidine in the treatment of functional bowel disorder
EP1539172A1 (en) * 2002-08-29 2005-06-15 Arachnova Therapeutics Ltd. New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidine
AU2003290363A1 (en) 2002-12-24 2004-07-22 Amedis Pharmaceuticals Ltd. Therapeutic use of selective noradrenaline reuptake inhibitors
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
BRPI0406749A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica

Also Published As

Publication number Publication date
NZ541009A (en) 2007-09-28
EP1567163B1 (en) 2007-04-11
DE602004005814D1 (de) 2007-05-24
US20040254172A1 (en) 2004-12-16
AU2004204827B2 (en) 2006-06-29
US7094786B2 (en) 2006-08-22
JP2006516977A (ja) 2006-07-13
WO2004062624A2 (en) 2004-07-29
US20040254171A1 (en) 2004-12-16
EP1567163A2 (en) 2005-08-31
ATE359079T1 (de) 2007-05-15
US20040147510A1 (en) 2004-07-29
KR20050094843A (ko) 2005-09-28
CA2512022A1 (en) 2004-07-29
WO2004062624A3 (en) 2005-04-07
EP1567163A4 (en) 2006-01-18
DE602004005814T2 (de) 2008-01-10
ES2285407T3 (es) 2007-11-16
MXPA05007379A (es) 2006-02-10
BRPI0406748A (pt) 2005-12-20
AU2004204827A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
PL378369A1 (pl) Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2003096929A8 (en) Improved pelvic health implants and methods
PL377239A1 (pl) Nowe amino-podstawione pochodne dihydropirymido [4,5-d]-pirymidynonu, ich wytwarzanie i zastosowanie jako środków framaceutycznych
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
AU2002251982A1 (en) Orthopedic implant and method for orthopedic treatment
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AUPR839001A0 (en) Dosage form, device and methods of treatment
PL363967A1 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
HK1047707A1 (zh) (+)-曲马朵、o-去甲曲马朵或(+)-o-去甲曲马朵、o-去甲-n-单-去甲-曲马朵或(+)-o-去甲-n-单-去甲-曲马朵治疗尿失禁的用途
WO2005105094A3 (en) Cancer treatment method
WO2005063757A3 (en) Novel crystalline forms of temozolomide
PT1469853E (pt) Utilização de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)-tieno[2,3-d]pirimidina para o tratamento da incontinência urinária
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
BR0312511A (pt) 4- (2-fluorofenil)-6-metil-2- (1-piperazinil) tieno [2,3-d] pirimidina no tratamento de distúrbio funcional dos intestinos
PL367401A1 (en) Utilization of buprenorphine in urinary incontinence therapy
GB0112494D0 (en) New therapeutic use
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
GB0216027D0 (en) New therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)